Medical AI startup Promedius (CEO Bae Hyun-jin) announced the introduction of an AI solution for early detection and management of musculoskeletal and metabolic diseases, including osteoporosis, at the 16th Congress of the Korean Sarcopenia Society 2024, held at Konkuk University Hospital.

The event was the first step taken by Promedius after signing a memorandum of understanding (MOU) with the Korean Sarcopenia Society to 'promote joint research and development of musculoskeletal-related solutions.’

PROS® CT: MQ, which Promedius introduced at the congress, is a solution that provides key metabolic indicators calculated by segmenting and measuring muscle and fat areas based on CT images of the abdomen and provides a report in a report format. We also introduced a technology for screening osteoporosis, which is closely related to sarcopenia, using chest X-rays, which attracted attention from academia and clinical practice. Given that both osteoporosis and sarcopenia are important health problems that appear during the aging process, early diagnosis is expected to play a significant role in the development of prevention and treatment strategies.

"AI technology has great potential in the field of musculoskeletal diseases, and its use is expected to increase in the future. The Korean Sarcopenia Society will work with Promedius to actively utilize AI technology to contribute to the promotion of public health in line with the needs of the times," Dr. Kim Duk-yoon, the Chairman of the Korean Sarcopenia Society, told the press.

Promedius also recently secured a Series A2 investment amidst an unfavorable sentiment within the investment market. The Series A2 investment was led by Starset Investment, a VC specializing in the biohealthcare sector, with new participants including Korea Investment Partners, Woori Venture Partners, and CRIT Ventures. In addition, strategic investments from DK Medical, a leading Korean X-ray manufacturer, and Big Move Ventures, the CVC of Bumin Hospital Group, are also included; along with the investment completion, Promedius’ extensive cooperation within the healthcare sector is anticipated.